Showcase Your Platform to IBD & Precision Medicine Decision Makers to Build Strategic Partnerships & Boost Your Visibility
As investment into precision medicine continues to accelerate across inflammatory bowel disease, drug developers are increasingly looking beyond a one-size-fits-all approach to treatment.
Despite significant advances in this field, challenges remain. Biopharma companies are still working to validate predictive and prognostic biomarkers, integrate multi-omic data sets, develop more precise clinical end points and build strategies that support more efficient trials and higher response rates. In turn, demand for specialized partners and innovative technologies is growing across every stage of the development journey.
Could you be the solution?
Attending Companies Include
What To Expect?
Put Your Expertise in Front of the Right Audience
Showcase how your capabilities support biomarker discovery, patient stratification, clinical development or data integration to help drug developers accelerate precision medicine adoption.
Meet the Leaders Driving the Next-Generation of IBD Therapies
Connect with the senior executives and scientific leaders at Roche, Merck, AbbVie, Xencor, Takeda, and more who are responsible for shaping precision medicine strategies.
Align Your Brand with the Future of IBD Drug Development
Be part of the conversations defining how molecular profiling, multi-omic data, AI, biomarkers, and combination therapies will improve treatment selection and stratify responders and non-responders.
Turn Strategic Conversations into Commercial Opportunities
Build relationships with companies actively evaluating new technologies, services and partnerships, creating connections that extend beyond the conference.
Key Services & Solutions
Our audience of precision medicine and IBD experts are actively seeking partners who specialize in:
AI, Bioinformatics & Computational Providers
Precision medicine depends on turning complex molecular and clinical data into actionable insights. Meet teams seeking AI and analytics partners to identify patient subgroups, discover biomarkers, and guide smarter development decisions.
Diagnostics, Multi-Omics & Biomarker Services
Biomarker-driven development is becoming central to patient selection and treatment optimization. Connect with leaders looking for diagnostic, testing, and multi-omics capabilities to advance IBD programs.
Preclinical CROs
As precision medicine advances in IBD, developers are seeking CRO partners that can generate translational data, validate targets, and de-risk development. Support biopharma to evaluate novel therapies and biomarkers before they reach the clinic.
Model & Organoid Providers
Providing human-relevant models that better capture the complexity and heterogeneity of Crohn’s and Colitis. Companies are looking for advanced organoid, ex vivo, and disease modelling platforms to improve translatability, evaluate treatment response and support biomarker discovery.
Audience Composition
Company Type
Attendee Seniority
*Audience Breakdown taken from the 4th Precision Medicine in Inflammatory Bowel Disease Summit
Explore Our Tailored Partnership Opportunities
Access a range of sponsorship packages designed to position your organization at alongside the leaders shaping the future of precision medicine in IBD.
Whether you provide biomarker technologies, AI platforms, data solutions or clinical development support, these opportunities enable you to connect directly with the industry’s key decision-makers:
Get in Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.
Iliaz Bushi
Partnerships Director